Boehringer said it will discontinue its virology research program following a review of its research areas and priorities. The company said, "the demands for medical innovation are shifting significantly" in virology due to the availability...

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will discontinue its virology research program following a review of its research areas and priorities. The company said, "The demands for medical innovation are shifting significantly" in virology...

The Medicines Patent Pool said it began negotiations for patents to HIV drugs from Boehringer and Bristol-Myers. The pool, established last year by UNITAID, allows companies to obtain a license to market generic versions of...

California State Controller John Chiang sent letters to eight companies requesting they extend and expand existing supplemental price reduction and rebate program for its HIV/AIDS drugs with California's AIDS Drug Assistance Program (ADAP). The Controller...

EMEA's CHMP issued a positive opinion to extend the indication for Aptivus tipranavir from Boehringer Ingelheim to include the treatment of HIV in highly pre-treated adolescents aged 12 and older resistant to multiple protease inhibitors...

FDA approved an sNDA for Aptivus tipranavir capsules for use in combination with ritonavir for treatment-experienced pediatric patients aged 2-18 years, which will be available shortly. The capsule formulation of the non-peptidic protease inhibitor (PI)...

A paper in the Journal of Clinical Investigation indicates that HIV protease inhibitors could be repurposed as neuroprotectants to block apoptosis in age-related macular degeneration, diabetic retinopathy and other conditions involving neuronal apoptosis. 1 The...

According to the foundation, Gilead and Boehringer committed to suspend increases in the prices of their HIV drugs for government agencies. The foundation wrote to nine companies to request price freezes in March. The foundation...